Literature DB >> 30052564

In Screening for Celiac Disease, Deamidated Gliadin Rarely Predicts Disease When Tissue Transglutaminase Is Normal.

Michelle J Gould1, Herbert Brill2,3,4, Margaret A Marcon1,5, Natalie J Munn6,7, Catharine M Walsh1,5,8,9.   

Abstract

OBJECTIVE: While tissue transglutaminase (tTG) antibodies are the most established serological test for celiac disease, newer deamidated gliadin peptide (DGP) screening tests are increasingly being completed. No pediatric study has systematically assessed the incidence of celiac disease in patients with an isolated positive DGP result. We sought to determine the positive predictive value of DGP serology for biopsy-confirmed celiac disease in pediatric patients with elevated DGP and normal tTG, to help guide clinicians' decision making when screening for this common condition and avoid unnecessary invasive follow-up diagnostic testing.
METHODS: A multicenter retrospective review of children, from birth to age 18, with isolated DGP immunoglobulin G (IgG) positive serology referred to 3 Canadian centers was completed. The positive predictive value of an isolated elevated DGP result was calculated.
RESULTS: Forty patients with DGP positive, tTG negative serology underwent endoscopy with duodenal biopsy. Of these, only 1 patient had biopsy-confirmed celiac disease. This patient was IgA deficient. This yields a positive predictive value of 2.5% (95% confidence interval 0.1%-14.7%) for isolated DGP IgG positive serology.
CONCLUSIONS: In isolation, DGP positive serology has a poor positive predictive value for celiac disease in children, especially in IgA sufficient individuals. Our findings suggest that DGP IgG testing should not be completed as part of the initial screening for celiac disease in the pediatric population as it does not effectively differentiate between individuals with and without the disease. Further research is needed to clarify to role of DGP IgG in children under the age of 2 and those with IgA deficiency.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30052564     DOI: 10.1097/MPG.0000000000002109

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  6 in total

Review 1.  The global burden of coeliac disease: opportunities and challenges.

Authors:  Govind K Makharia; Prashant Singh; Carlo Catassi; David S Sanders; Daniel Leffler; Raja Affendi Raja Ali; Julio C Bai
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-01-03       Impact factor: 46.802

2.  Diagnostic Value of Immunoglobulin G Anti-Deamidated Gliadin Peptide Antibody for Diagnosis of Pediatric Celiac Disease: A Study from Shiraz, Iran.

Authors:  Mohammad Hossein Anbardar; Fatemeh Golbon Haghighi; Naser Honar; Mozhgan Zahmatkeshan
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2022-07-06

3.  Can We Ignore the Utility of Deamidated Gliadin Peptide in the Diagnosis of Celiac Disease in Children?

Authors:  Leslie Mataya; Jocelyn Silvester; Hilary Jericho
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-07       Impact factor: 2.839

4.  Diagnosis of gluten-related enteropathy in a newborn: how and when?

Authors:  Roberto Assandri; Alessandro Montanelli
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019

5.  Population-based screening for celiac disease reveals that the majority of patients are undiagnosed and improve on a gluten-free diet.

Authors:  Jan-Magnus Kvamme; Sveinung Sørbye; Jon Florholmen; Trond S Halstensen
Journal:  Sci Rep       Date:  2022-07-25       Impact factor: 4.996

6.  Isolated positive deamidated gliadin peptide-IgG has limited diagnostic utility in coeliac disease.

Authors:  Nikil Vootukuru; Harveen Singh; Edward Giles
Journal:  J Paediatr Child Health       Date:  2022-06-21       Impact factor: 1.929

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.